Objective To explore the clinical efficacy of pulmonary surfactant (PS) with intermittent positive nasal pressure ventilation (NIPPV), warmed and humidified high-flow positive nasal pressure ventilation (HHFNC) and nasal pronged continuous positive airway pressure (NCPAP) in the treatment of neonatal respiratory distress syndrome (NRDS). Methods A total of 90 preterm infants with NRDS curatived to our hospital from May 2022 to May 2024 were selected as the study subjects, and they were divided evenly into three groups according to the random number table method. The NIPPV group was treated with NIPPV, the HHFNC group was treated with HHFNC, and the NCPAP group was treated with NCPAP. Blood gas indexes, oxygen therapy, invasive ventilation and complications were compared between the three groups. Results There was no significant difference in blood gas indexes between the three groups at 0 h and 48 h (P>0.05), PaO2 and PaO2/FiO2 in the NIPPV group were higher than those in the HHFNC group and NCPAP group at 12 h, PaCO2 was lower than that in the control group, PaO2 and PaO2/FiO2 were higher and PaCO2 were lower in the NIPPV group and HHFNC group than those in the NCPAP group at 24 h (P<0.05). The duration of non-invasive ventilation was statistically shorter than that of the HHFNC group and the NCPAP group (P<0.05), and the rate of invasive ventilation and complications in the NIPPV group and HHFNC group were lower than those in the NCPAP group (P<0.05). Conclusion NIPPV treatment of NRDS can improve blood gas indexes faster, shorten the duration of oxygen therapy and non-invasive ventilation, and reduce the rate of invasive ventilation, which is safe and reliable.
Key words
neonatal respiratory distress syndrome /
surfactant in the lungs /
nasal intermittent positive pressure ventilation /
different modes of ventilation /
Blood gas markers
{{custom_keyword}} /
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 樊宏燕.无创经鼻塞式双水平正压通气联合猪肺磷脂注射液治疗新生儿呼吸窘迫综合征疗效观察[J].中国药物与临床,2021,21(11):1925-1926.
[2] 冯晓霞,宋红,周川,等.微创肺表面活性物质治疗及无创高频辅助通气在极低及超低出生体质量儿呼吸窘迫综合征治疗中的应用[J].中华实用儿科临床杂志,2020,35(18):1388-1393.
[3] 那利,朱江伟,刘聪瑞,等.对比分析间歇正压通气与无创高频振荡通气分别联合微创肺表面活性物质治疗新生儿呼吸窘迫综合征疗效及安全性[J].现代生物医学进展,2023,23(10):1924-1928.
[4] 杨云莲,张鹏,郭平佳.无创正压通气联合肺表面活性物质治疗新生儿呼吸窘迫综合征的疗效及对患儿血气指标的影响[J].中国妇幼保健,2021,36(11):2553-2555.
[5] 刘颖,聂川,颜慧恒,等.经鼻无创高频振荡通气与持续气道正压通气在早产儿呼吸窘迫综合征初始治疗中的效果比较[J].广东医学,2020,41(3):229-233.
[6] 吴杰斌,翟敬芳,刘枭,等.无创高频与加温湿化高流量鼻导管通气在早产儿呼吸窘迫综合征序贯撤机的临床应用[J].中国小儿急救医学,2021,28(3):165-170.
[7] 亚太卫生健康协会儿科医学分会,亚太卫生健康协会儿科医学分会重症超声医学专业委员会,世界重症超声联盟中国联盟,等.新生儿呼吸窘迫综合征超声诊断与分度专家共识[J].中国小儿急救医学,2021,28(7):545-551.
[8] 徐仕霞.无创高频震荡通气联合肺表面活性物质治疗新生儿呼吸窘迫综合征的临床研究[J].实用临床医药杂志,2020,24(8):29-32.
[9] 郝新华,贺红岩,王梦莹.高频振荡通气序贯不同无创通气模式治疗早产儿呼吸窘迫综合征的效果分析[J].中国临床医生杂志,2020,48(7):865-868.
[10] 郭梅,王奇伟,刘鼎立,等.无创高频震荡通气在新生儿呼吸窘迫综合征治疗中的应用[J].中华全科医学,2021,19(9):1514-1517,1556.
[11] 滕沁伶,刘章英,贺晓春.呼吸机无创高频振荡通气在极低出生体质量儿呼吸窘迫综合征42例中的疗效分析[J].安徽医药,2022,26(1):172-175.
[12] 杨丽,易明,彭周杰,等.无创高频振荡通气在极低出生体质量儿呼吸窘迫综合征的早期应用[J].中华实用儿科临床杂志,2021,36(20):1555-1558.
[13] 刘晓玲,朱芳艮,阮仁伟,等.不同无创呼吸机支持模式治疗新生儿呼吸窘迫综合征的临床效果[J].皖南医学院学报,2023,42(5):454-457.
[14] 张慧,彭万胜.NIPPV和NCPAP联合LISA技术治疗早产儿呼吸窘迫综合征效果观察[J].山东医药,2022,62(22):71-74.
[15] 李莹莹,戴立英,朱峰,等.NHFOV、NIPPV、NCPAP疗法在早产儿呼吸窘迫综合征治疗中的应用对比观察[J].山东医药,2022,62(18):72-76.
{{custom_fnGroup.title_en}}
Footnotes
{{custom_fn.content}}